Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Effects on heart rate

This article was originally published in The Tan Sheet

Executive Summary

Energy drinks, most of which contain high levels of caffeine and amino acid taurine, increase blood pressure and heart-rate levels, according to results of Wayne State (Mich.) University research. Over the duration of the study, subjects' heart rates increased five to seven beats per minute and systolic blood pressure increased 10 mmHg. "Individuals with high blood pressure and heart disease should be advised to avoid these drinks," says James Kalus, pharmacist and senior manager of patient care services at Henry Ford Hospital in Detroit. While the product used in the study had as much caffeine as one to two cups of coffee, others contain "much higher levels," said Kalus. Researchers are unsure what effect exercise or combining the products with alcohol has on users, but several state attorneys general concerned with health claims in alcoholic-energy-drink advertising are calling for greater federal enforcement against the practice (1"The Tan Sheet" Sept. 3, 2007, p. 14)...

You may also be interested in...



State Officials Seek To Drain Health Claims From Alcoholic Energy Drink Ads

Several state attorneys general concerned with health-related statements in alcoholic energy drink advertising designed to attract young people are calling for greater federal enforcement against the practice

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims

Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel